Close Menu

NEW YORK (GenomeWeb) – With the launch last year of its PCR-based GeneStrat liquid biopsy test for non-small cell lung cancer and the release of a next-generation sequencing test planned for later this year, Biodesix continues to expand its offerings with the aim of addressing additional points in the NSCLC care pathway.

According Paul Beresford, the company's chief business officer, the move into genetic testing has also helped drive sales of Biodesix's flagship product, Veristrat, a proteomic test for assessing a patient's prognosis and predicting response to drug treatment.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.